HTML Microdata document

This HTML5 document contains 59 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n19	http://linked.opendata.cz/resource/drugbank/drug/DB00234/identifier/pubchem-compound/
n2	http://linked.opendata.cz/resource/drugbank/drug/
dcterms	http://purl.org/dc/terms/
n20	http://linked.opendata.cz/resource/drugbank/drug/DB00234/identifier/pubchem-substance/
n15	http://linked.opendata.cz/resource/mesh/concept/
n17	http://linked.opendata.cz/resource/drugbank/drug/DB00234/identifier/drugbank/
n4	http://bio2rdf.org/drugbank:
adms	http://www.w3.org/ns/adms#
n16	http://linked.opendata.cz/resource/drugbank/drug/DB00234/identifier/chemspider/
n10	http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n5	http://linked.opendata.cz/ontology/drugbank/
n14	http://linked.opendata.cz/ontology/mesh/
owl	http://www.w3.org/2002/07/owl#
n8	http://linked.opendata.cz/resource/drugbank/drug/DB00234/identifier/pharmgkb/
n9	http://linked.opendata.cz/resource/drugbank/drug/DB00234/identifier/wikipedia/
n6	http://linked.opendata.cz/resource/drugbank/property/
xsdh	http://www.w3.org/2001/XMLSchema#
n18	http://linked.opendata.cz/resource/drugbank/drug/DB00234/identifier/bindingdb/
n12	http://linked.opendata.cz/resource/atc/
n11	http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item: n2:DB00234
rdf:type: n5:Drug
n5:description: Reboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD. Its mesylate (i.e. methanesulfonate) salt is sold under tradenames including Edronax, Norebox, Prolift, Solvex, Davedax or Vestra. Reboxetine has two chiral centers, but it only exists as two enantiomers, (R,R)-(-)- and (S,S)-(+)-reboxetine.
n5:generalReferences: # Fleishaker JC: Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet. 2000 Dec;39(6):413-27. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11192474 # Edwards DM, Pellizzoni C, Breuel HP, Berardi A, Castelli MG, Frigerio E, Poggesi I, Rocchetti M, Dubini A, Strolin Benedetti M: Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. Biopharm Drug Dispos. 1995 Aug;16(6):443-60. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7579027 # Wienkers LC, Allievi C, Hauer MJ, Wynalda MA: Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes. Drug Metab Dispos. 1999 Nov;27(11):1334-40. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10534319 # Kasper S, el Giamal N, Hilger E: Reboxetine: the first selective noradrenaline re-uptake inhibitor. Expert Opin Pharmacother. 2000 May;1(4):771-82. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11249515 # Fleishaker JC: Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet. 2000 Dec;39(6):413-27. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11192474
n5:group: investigational approved
n5:halfLife: 12.5 hours
n5:indication: For the treatment of clinical depression.
owl:sameAs: n4:DB00234 n10:DB00234
dcterms:title: Reboxetine
adms:identifier: n8:PA144614921 n9:Reboxetine n16:59268 n17:DB00234 n18:35226 n19:65856 n20:46504845
n5:mechanismOfAction: Reboxetine is a selective inhibitor of noradrenaline reuptake. It inhibits noradrenaline reuptake in vitro to a similar extent to the tricyclic antidepressant desmethylimipramine. Reboxetine does not affect dopamine or serotonin reuptake and it has low in vivo and in vitro affinity for adrenergic, cholinergic, histaminergic, dopaminergic and serotonergic receptors.
n5:synonym: (S S)-Reboxetine SID11114256 Reboxetine Esreboxetine
n5:toxicity: Reports of seizures (rare) have been reported
n5:proteinBinding: 98%
n5:salt
n14:hasConcept: n15:M0201546
n5:IUPAC-Name: n6:271B622A-363D-11E5-9242-09173F13E4C5
n5:InChI: n6:271B6230-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula: n6:271B622F-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight: n6:271B622C-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight: n6:271B622D-363D-11E5-9242-09173F13E4C5
n5:SMILES: n6:271B622E-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility: n6:271B6228-363D-11E5-9242-09173F13E4C5 n6:271B623F-363D-11E5-9242-09173F13E4C5
n5:logP: n6:271B6229-363D-11E5-9242-09173F13E4C5 n6:271B6226-363D-11E5-9242-09173F13E4C5 n6:271B6241-363D-11E5-9242-09173F13E4C5
n5:logS: n6:271B6227-363D-11E5-9242-09173F13E4C5
n11:hasATCCode: n12:N06AX18
n5:H-Bond-Acceptor-Count: n6:271B6236-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count: n6:271B6237-363D-11E5-9242-09173F13E4C5
n5:InChIKey: n6:271B6231-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-: n6:271B6232-363D-11E5-9242-09173F13E4C5
n5:Polarizability: n6:271B6234-363D-11E5-9242-09173F13E4C5
n5:Refractivity: n6:271B6233-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count: n6:271B6235-363D-11E5-9242-09173F13E4C5
n5:absorption: Reboxetine is rapidly and extensively absorbed following oral administration.
n5:affectedOrganism: Humans and other mammals
n5:casRegistryNumber: 98769-81-4
n5:Bioavailability: n6:271B623B-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter: n6:271B623D-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule: n6:271B623E-363D-11E5-9242-09173F13E4C5
n5:Melting-Point: n6:271B6240-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings: n6:271B623A-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge: n6:271B6239-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five: n6:271B623C-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name: n6:271B622B-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-: n6:271B6238-363D-11E5-9242-09173F13E4C5